Clinical Trial Update: Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of Grass Pollen-derived Peptides for seasonal allergic rhinitis has completed, focusing on safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• Grass pollen-derived peptides

Snippet

Sponsor: BioTech Tools S.A. | Conditions: Seasonal Allergic Rhinoconjunctivitis | Phase 1 | Status: COMPLETED